C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study.

Annette BruchfeldHasan MaginPatrick NachmanSamir ParikhRichard LafayetteAntonia PotarcaShichang MiaoPirow Bekker

Published in: Clinical kidney journal (2022)

This short-term pilot study showed an improvement in the slope of the UPCR, with ∼50% improvement in three of seven patients with IgAN. Longer avacopan treatment duration may be indicated for maximal benefit.

Keyphrases

heart rate
resistance training
blood pressure
combination therapy